| Description | Methoxyamine HCl (Methoxyamine) covalently binds to apurinic/apyrimidinic (AP) DNA damage sites and inhibits base excision repair (BER), which may result in an increase in DNA strand breaks and apoptosis. Methoxyamine is an orally bioavailable small molecule inhibitor with potential adjuvant activity. This agent may potentiate the anti-tumor activity of alkylating agents. |
| Synonyms | 甲氧基胺盐酸盐, TRC102, TRC 102, Methoxyamine, TRC-102 |
| molecular weight | 83.51 |
| Molecular formula | CH6ClNO |
| CAS | 593-56-6 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Solubility | H2O: Soluble DMSO: 55 mg/ml (658.6 mM) |
| References | 1. She MR, Guo KY, Niu XQ, Lu XX. [Effects of manumycin combined with methoxyamine on apoptosis in myeloid leukemia U937 cells]. Ai Zheng. 2008 Aug;27(8):835-9. Chinese. PubMed PMID: 18710617. 2. Yan L, Bulgar A, Miao Y, Mahajan V, Donze JR, Gerson SL, Liu L. Combined treatment with temozolomide and methoxyamine: blocking apurininc/pyrimidinic site repair coupled with targeting topoisomerase IIalpha. Clin Cancer Res. 2007 Mar 1;13(5):1532-9. PubMed PMID: 17332299. 3. Yan T, Seo Y, Schupp JE, Zeng X, Desai AB, Kinsella TJ. Methoxyamine potentiates iododeoxyuridine-induced radiosensitization by altering cell cycle kinetics and enhancing senescence. Mol Cancer Ther. 2006 Apr;5(4):893-902. PubMed PMID: 16648559. |